Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034

Exclusion Criteria

• •History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 6 months prior to beginning study treatment. Screening with CNS imaging studies (CT scan or MRI) is required only if clinically indicated or if the subject has a history of CNS metastases.
• •Clinically significant gastrointestinal (GI) abnormalities including, but not limited to: malabsorption syndrome, history of resection of the stomach or small bowel, active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis or other conditions that increase the risk for perforation, history of abdominal fistula, GI perforation or intra-abdominal abscess within 4 weeks prior to beginning study treatment.
• •Presence of uncontrolled infection.
• •Corrected QT interval (QTc) \> 480 msec.
• •History of any one or more of the following cardiovascular conditions within the past 6 months: congestive heart failure, cardiac angioplasty or stenting, myocardial infarction, unstable angina OR symptomatic peripheral vascular disease.
• •Has poorly controlled hypertension (systolic blood pressure \[SBP\] \>/ 140 mmHg, or diastolic blood pressure \[DBP\] \>/ 90 mmHg).
• •Note: Initiation or adjustment of anti-hypertensive medication(s) is permitted prior to study entry. The blood pressure (BP) must be re-assessed on 2 occasions that are separated by a minimum of 24 hours. The mean SBP/DBP values from both BP assessments must be \< 140/90 mmHg in order for a subject to be eligible for the study.
• •History of cerebrovascular accident or pulmonary embolism within the past 6 months.
• •History of untreated deep venous thrombosis (DVT) within the past 6 months.
• •Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible.
• •Prior major surgery or trauma within the past 28 days or presence of any wound, fracture or ulcer which is not fully healed.
• •Evidence of active bleeding, bleeding diathesis or hemoptysis within 6 weeks prior to study treatment.
• •Use of prohibited medications within the timeframes specified in Section 9.2, Prohibited Medications of the protocol.
• •Use of an investigational agent, including an investigational anti-cancer agent within 28 days or 5 half-lives, whichever is longer, preceding the first dose of pazopanib.
• •Treatment with any cancer therapy (including chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery or tumor embolization) within 14 days prior to the first dose of pazopanib.
• •Note: Current treatment with leuprolide is permitted.
• •Any ongoing potentially reversible toxicity from prior anti-cancer therapy that is \> Grade 1 or any toxicity from prior anti-cancer therapy that is progressing in severity.
• •Any serious and/or unstable pre-existing medical, psychiatric, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study, including any condition that could interfere with the accurate assessment and recovery of \[14C\].
• •History or presence of hepatic or renal disease or any other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs